The development activities of Ventaleon GmbH focus on clinical research in novel antiviral agents applied via inhalation.
A first proof-of-concept study was finished successfully in 2015 investigating the inhaled application of the active substance LASAG in hospitalized patients with severe Influenza infection. It clearly showed that LASAG reduces the time to resolution of influenza symptoms to a greater extent than current standard of care treatment in patients with moderate to severe symptoms.
Future development will focus on the replication of these results en route to a marketing authorization for inhaled LASAG.
For more information, please click on the following picture: